Pharmacokinetic and pharmacodynamic evaluation of tigecycline

Bibliography

• Giamarellou H, Poulakou G. Multidrug-resistant gram-negative infections. What are the treatment options? Drugs 2009;69:1879-901
   PubMed Web of Science ®Google Scholar
• Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41(Suppl 5):S303-14
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth. Diagn Microbiol Infect Dis 2007;59:347-9
   PubMed Web of Science ®Google Scholar
• Kasbekar N. Tigecycline: a new glycylcycline antimicrobial agent. Am J Health Syst Pharm 2006;63:1235-43
   PubMed Web of Science ®Google Scholar
• Letter to Wyeth Pharmaceuticals, Inc. Department of Health & Human Services. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021821s013,021821s017,021821s018ltr.pdf [Accessed 17 May 2011]
   Google Scholar
• Questions and answers on the withdrawal of the application for a change to the marketing authorization for tygacil. EMEA. Doc. Ref. EMEA/245771/2008 Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/tygacil/24577108en.pdf [Accessed 17 May 2011]
   Google Scholar
• Tygacil: for the withdrawal of type II variation application linked to an extension of indication for a medicinal product already authorized in the European Union. EMEA. Withdrawal of variation application EMEA/H/C/644/II/13 for community acquired pneumonia. 2008. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/tygacil/withdrawalletter.pdf [Accessed 17 May 2011]
   Google Scholar
• Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008;46:1121-2
   PubMed Web of Science ®Google Scholar
• Cercenado E, Cercenado S, Gomez JA, In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 2003;52:138-9
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob Agents Chemother 2006;50:3507-13
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001;40:173-7
   PubMed Web of Science ®Google Scholar
• Milatovic D, Schmitz FJ, Verhoef J, Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003;47:400-4
   PubMed Web of Science ®Google Scholar
• Souli M, Kontopidou FV, Koratzanis E, In vitro activity of tigecycline against multiple-drug resistant, including pan-resistant, Gram-negative and Gram-positive, clinical isolates form Greek hospitals. Antimicrob Agents Chemother 2006;50:3166-9
   PubMed Web of Science ®Google Scholar
• Bouchillon SK, Iredell JR, Barkham T, Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Int J Antimicrob Agents 2009;33:130-6
   PubMed Web of Science ®Google Scholar
• Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther 2008;30:2040-50
   PubMed Web of Science ®Google Scholar
• BSAC methods for antimicrobial susceptibility testing, Version 7.1, February 2008. BSAC, British Society for Antimicrobial Chemoptherapy. Available from: http://www.bsac.org.uk/_db/_documents/version_7_1_february_2008.pdf [Assessed 19 May 2011]
   Google Scholar
• Castanheira M, Sader HS, Deshpande LM, Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008;52:570-3
   PubMed Web of Science ®Google Scholar
• Pankey GA. Tigecycline. J Antimicrob Chemother 2005;56:470-80
   PubMed Web of Science ®Google Scholar
• Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000;16:61-3
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002;46:3164-7
   PubMed Web of Science ®Google Scholar
• Dean CR, Visalli MA, Projan SJ, Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003;47:972-8
   PubMed Web of Science ®Google Scholar
• Tygacil® [package insert]. Wyeth Pharmaceuticals Co., a subsidiary of Pfizer, Inc. Revised: 01/2011
   Google Scholar
• Performance standards for antimicrobial susceptibility tests: approved standard M100-S21. 21st edition. Clinical and Laboratory Standards Institute. CLSI; Wayne (PA): 2011
   Google Scholar
• Tetracyclines-EUCAST clinical MIC breakpoints: tigecycline. Available from: http://www.srga.org/eucastwt/MICTAB/MICtetracyclines.htm [Assessed 19 May 2011]
   Google Scholar
• Jones RN, Ferraro MJ, Reller LB, Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007;45:227-30
   PubMed Web of Science ®Google Scholar
• Moland ES, Craft DW, Hong SG, In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. Antimicrob Agents Chemother 2008;52:2940-2
   PubMed Web of Science ®Google Scholar
• Vouillamoz J, Moreillon P, Giddey M, In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens. J Antimicrob Chemother 2008;61:371-4
   PubMed Web of Science ®Google Scholar
• Scheetz MH, Qi C, Warren JR, In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or –resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:1621-6
   PubMed Web of Science ®Google Scholar
• Sands M, McCarter Y, Sanchez W. Synergy testing of multidrug resistant Acinetobacter baumanii against tigecycline and polymyxin using an E-test methodology. Eur J Clin Microbiol Infect Dis 2007;26:521-2
   PubMed Web of Science ®Google Scholar
• Available from: www.drugbank.ca/drugs/DB00560 [Accessed 28 August 2011]
   Google Scholar
• Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006;58:256-65
   PubMed Web of Science ®Google Scholar
• Hoffman M, DeMaio W, Jordan RA, Metabolism, Excretion, and Pharmacokinetics of [14C]Tigecycline, a First-In-Class Glycylcycline Antibiotic, after Intravenous Infusion to Healthy Male Subjects. Drug Metab Dispos 2007;35:1543-53
   PubMed Web of Science ®Google Scholar
• Muralidharan G, Micalizzi M, Speth J, Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-9
   PubMed Web of Science ®Google Scholar
• Meagher AK, Ambrose PG, Grasela TH, Pharmacokinetic/pharmacodynamic profile for tigecycline - a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005;52:165-71
   PubMed Web of Science ®Google Scholar
• Muralidharan G, Fruncillo RJ, Micalizzi M, Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005;49:1656-9
   PubMed Web of Science ®Google Scholar
• Meagher A, Cirincione B, Piedmonte M, Pharmacokinetics of tigecycline in healthy adult volunteers and in subjects with renal impairment [abstract1023]. Clin Microbiol Infect 2004;10(Suppl 3):274
   Google Scholar
• Darling IM, Cirincione BB, Owens JS. Non-compartmental pharmacokinetics of tigecycline in Phase 3 studies of patients with complicated skin and skin structure and intra abdominal infections [abstract A-20]. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; Washington, DC, USA; 2005. p. 17
   Google Scholar
• Korth-Bradley JM, Baird-Bellaire SJ, Patat AA, Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. J Clin Pharmacol 2011;51:93-10
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37:840-51
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Cwik M, Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006;58:1221-9
   PubMed Web of Science ®Google Scholar
• Sun HK, Ong CT, Umer A, Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005;49:1629-32
   PubMed Web of Science ®Google Scholar
• Bulik CC, Wiskirchen DE, Shepard A, Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 2010;54:5209-13
   PubMed Web of Science ®Google Scholar
• Burkhardt O, Rauch K, Kaever V, Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 2009;34:101-2
   PubMed Web of Science ®Google Scholar
• Conte JE Jr, Golden JA, Kelly MG, Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005;25:523-9
   PubMed Web of Science ®Google Scholar
• Pichardo C, Pachon-Ibanez ME, Docobo-Perez F, Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia. Eur J Clin Microbiol Infect Dis 2010;29:527-31
   PubMed Web of Science ®Google Scholar
• Rubino CM, Forrest A, Bhavnani SM, Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia. Antimicrob Agents Chemother 2010;54:5180-6
   PubMed Web of Science ®Google Scholar
• Tombs NL, Chaudary I, Conant R, Tissue distribution of Gar-936, a broad-spectrum antibiotic, in male rats [abstract 39]. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; San Francisco, CA, USA; 1999. p. 302
   Google Scholar
• Ji AJ, Saunders JP, Amorusi P, A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS. J Pharm Biomed Anal 2008;48:866-75
   PubMed Web of Science ®Google Scholar
• Mouton JW. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin North Am 2003;17:579-98
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Labthavikul P, Jones CH, In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006;57:573-6
   PubMed Web of Science ®Google Scholar
• Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002;22:1517-23
   PubMed Web of Science ®Google Scholar
• van Ogtrop ML, Andes D, Stamstad TJ, In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000;44:943-9
   PubMed Web of Science ®Google Scholar
• Lefort A, Lafaurie M, Massias L, Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003;47:216-22
   PubMed Web of Science ®Google Scholar
• Meagher AK, Passarell JA, Cirincione BB, Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007;51:1939-45
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Meagher AK, Passarell JA, Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn Microbiol Infect Dis 2009;63:155-9
   PubMed Web of Science ®Google Scholar
• Passarell JA, Meagher AK, Liolios K, Exposure-response analyses of the efficacy of tigecycline in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008;52:204-10
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Meagher AK, Passarell JA, Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints. Diagn Microbiol Infect Dis 2009;63:38-42
   PubMed Web of Science ®Google Scholar
• Kuti JL, Dowzicky M, Nicolau DP. Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections. Surg Infect (Larchmt) 2008;9:57-66
   PubMed Web of Science ®Google Scholar
• Crandon JL, Kim A, Nicolau DP. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J Antimicrob Chemother 2009;64:837-9
   PubMed Web of Science ®Google Scholar
• Koomanachai P, Crandon JL, Banevicius MA, Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob Agents Chemother 2009;53:5060-3
   PubMed Web of Science ®Google Scholar
• Wiskirchen DE, Koomanachai P, Nicasio AM, In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother 2011;55:1420-7
   PubMed Web of Science ®Google Scholar
• Nicasio AM, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009;53:2756-61
   PubMed Web of Science ®Google Scholar
• Ong CT, Babalola CP, Nightingale CH, Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 2005;56:498-501
   PubMed Web of Science ®Google Scholar
• Dandache P, Nicolau DP, Sakoulas G. Tigecycline for the treatment of multidrug-resistant Klebsiella pneumoniae meningitis. Infect Dis Clin Pract 2009;17:66-8
   Google Scholar
• Giamarellou H. Multidrug-resistant gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents 2010;36(Suppl 2):S50-4
   PubMed Web of Science ®Google Scholar
• Freire AT, Melnyk V, Kim MJ, ; 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140-51
   PubMed Web of Science ®Google Scholar
• Nguyen M, Eschenauer GA, Bryan M, Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 2010;67:180-4
   PubMed Web of Science ®Google Scholar
• Peleg AY, Potoski BA, Rea R, Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31
   PubMed Web of Science ®Google Scholar
• Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009;63:775-80
   PubMed Web of Science ®Google Scholar
• Garcia-Cabrera E, Jimenez-Mejias ME, Gil Navarro MV, Superinfection during treatment of nosocomial infections with tigecycline. Eur J Clin Microbiol Infect Dis 2010;29:867-71
   PubMed Web of Science ®Google Scholar
• Frampton JE, Curran MP. Tigecycline. Drugs 2005;65:2623-35
   PubMed Web of Science ®Google Scholar
• Chen LY, Chen TC, Chen YH, Microbial isolation and emergence of antimicrobial resistance associated with tigecycline usage. J Microbiol Immunol Infect 2011; doi:10.1016/j.jmii.2011.01.033
   Google Scholar
• Cui JC, Liu YN, Chen LA. Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii. J Antibiot (Tokyo) 2010;63:29-31
   PubMed Web of Science ®Google Scholar
• Parsonage M, Shah S, Moss P, Breakthrough bacteraemia with a susceptible Enterococcus faecalis during tigecycline monotherapy. J Antimicrob Chemother 2010;65:370-4
   PubMed Web of Science ®Google Scholar
• Poulakou G, Kontopidou FV, Paramythiotou E, Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 2009;58:273-84
   PubMed Web of Science ®Google Scholar
• Principe L, D’Arezzo S, Capone A, Petrosillo N. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 2009;8:18
   PubMed Web of Science ®Google Scholar